Organon & Co
OGN10.450USD
-0.400-3.69%
收盘 09/19, 16:00（美东）报价延迟15分钟
2.72B总市值
3.88市盈率 TTM
关于 Organon & Co 公司
Organon & Co. 是一家全球医疗保健公司。该公司致力于通过一系列处方疗法和女性健康领域的医疗设备、生物仿制药以及一系列治疗领域的成熟药物特许经营权来开发和提供健康解决方案。该公司拥有一系列避孕和生育品牌，包括 Nexplanon、NuvaRing 和 Follistim AQ。其生物仿制药产品组合涵盖免疫学和肿瘤学治疗。该公司还拥有一系列成熟品牌，包括心血管、皮肤病学和非阿片类止痛药领域的品牌。该公司通过各种渠道销售这些产品，包括药品批发商和零售商、医院、政府机构和管理医疗保健提供商，如药房福利管理机构和其他机构。该公司的产品组合还包括 1% VTAMA（tapinarof）乳膏，这是一种非生物、非甾体外用疗法，用于治疗成人轻度、中度和重度斑块状银屑病。
公司简介
公司代码OGN
公司名称Organon & Co
上市日期May 14, 2021
CEOMr. Kevin Ali
员工数量10000
证券类型Ordinary Share
年结日May 14
公司地址30 Hudson Street
城市JERSEY CITY
上市交易所NYSE Consolidated
国家United States of America
邮编07302
电话15514306000
网址https://www.organon.com/
公司代码OGN
上市日期May 14, 2021
CEOMr. Kevin Ali
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
地区USD
名称
营收
占比
United States
412.00M
27.23%
Europe and Canada
376.00M
24.85%
Asia Pacific and Japan
251.00M
16.59%
Latin America, Middle East, Russia and Africa
240.00M
15.86%
China
204.00M
13.48%
Other
30.00M
1.98%
业务
地区
业务USD
名称
营收
占比
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.37%
BlackRock Institutional Trust Company, N.A.
10.88%
MFS Investment Management
3.89%
State Street Global Advisors (US)
3.66%
Millennium Management LLC
3.50%
其他
65.71%
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.37%
BlackRock Institutional Trust Company, N.A.
10.88%
MFS Investment Management
3.89%
State Street Global Advisors (US)
3.66%
Millennium Management LLC
3.50%
其他
65.71%
股东类型
持股股东
占比
Investment Advisor
49.77%
Investment Advisor/Hedge Fund
21.12%
Hedge Fund
7.63%
Research Firm
2.67%
Pension Fund
1.85%
Bank and Trust
0.88%
Sovereign Wealth Fund
0.87%
Individual Investor
0.35%
Family Office
0.03%
其他
14.83%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
2023Q1
2044
204.79M
80.50%
-21.41M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
29.61M
11.39%
-704.86K
-2.33%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.91M
11.12%
-948.87K
-3.18%
Mar 31, 2025
MFS Investment Management
10.58M
4.07%
+827.89K
+8.49%
Mar 31, 2025
State Street Global Advisors (US)
8.98M
3.45%
-358.52K
-3.84%
Mar 31, 2025
LSV Asset Management
7.98M
3.07%
+455.70K
+6.06%
Mar 31, 2025
UBS Financial Services, Inc.
1.68M
0.65%
-1.52M
-47.56%
Mar 31, 2025
Citadel Advisors LLC
4.01M
1.54%
+4.01M
+1138441.76%
Mar 31, 2025
Nordea Funds Oy
4.85M
1.87%
-1.89M
-28.08%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.17M
1.6%
+884.26K
+26.92%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
SPDR S&P Pharmaceuticals ETF
3.64%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.25%
Alger Russell Innovation ETF
2.2%
First Trust NASDAQ Pharmaceuticals ETF
1.91%
First Trust Health Care Alphadex Fund
1.75%
Invesco S&P SmallCap Health Care ETF
1.7%
Global X SuperDividend U.S. ETF
1.36%
iShares U.S. Pharmaceuticals ETF
1.24%
ALPS O'Shares US Small-Cap Quality Dividend ETF
1.01%
Harbor Long-Short Equity ETF
0.86%
查看更多
SPDR S&P Pharmaceuticals ETF
占比3.64%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比2.25%
Alger Russell Innovation ETF
占比2.2%
First Trust NASDAQ Pharmaceuticals ETF
占比1.91%
First Trust Health Care Alphadex Fund
占比1.75%
Invesco S&P SmallCap Health Care ETF
占比1.7%
Global X SuperDividend U.S. ETF
占比1.36%
iShares U.S. Pharmaceuticals ETF
占比1.24%
ALPS O'Shares US Small-Cap Quality Dividend ETF
占比1.01%
Harbor Long-Short Equity ETF
占比0.86%
分红派息
近5年累计派现
1.03B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
May 04, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 15, 2023 going ex on May 12, 2023
May 15, 2023
Jun 15, 2023
May 12, 2023
Feb 16, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 16, 2023 going ex on Feb 24, 2023
Feb 27, 2023
Mar 16, 2023
Feb 24, 2023
Nov 03, 2022
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 15, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Dec 15, 2022
Nov 10, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
